Skip to main content

Amtagvi Disease Interactions

There are 4 disease interactions with Amtagvi (lifileucel).

Moderate

Lifileucel (applies to Amtagvi) cardiac/vascular disorders

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Heart Disease, Cardiovascular Disease, History - Myocardial Infarction

Patients treated with lifileucel have exhibited cardiac disorders. Prior to administration of lifileucel, assess patients for a history of cardiac/vascular disorders or for current use of anticoagulants. Monitor patients with signs and symptoms of cardiac disorders before and after infusion of lifileucel.

References

  1. (2024) "Product Information. Amtagvi (lifileucel)." Iovance Biotherapeutics Manufacturing LLC
Moderate

Lifileucel (applies to Amtagvi) infections

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Lifeleucel should not be administered to patients with active infection or inflammatory disorders. Monitor patients for signs or symptoms of infection before and after infusion of lifileucel; treat appropriately as indicated. Administer prophylactic antimicrobials according to institutional guidelines.

References

  1. (2024) "Product Information. Amtagvi (lifileucel)." Iovance Biotherapeutics Manufacturing LLC
Moderate

Lifileucel (applies to Amtagvi) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Patients treated with lifileucel may develop worsened renal function. Prior to administration of lifileucel, assess patients for a history of renal impairment. Monitor patients with signs and symptoms of acute renal failure before and after infusion of lifileucel. Withhold or discontinue lifileucel infusion if severe acute renal injury is evidenced.

References

  1. (2024) "Product Information. Amtagvi (lifileucel)." Iovance Biotherapeutics Manufacturing LLC
Moderate

Lifileucel (applies to Amtagvi) respiratory disorders

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Pulmonary Impairment

Patients treated with lifileucel may develop worsened respiratory function. Prior to administration of lifileucel, assess patients for a history of respiratory disorders. Monitor patients with signs and symptoms of respiratory failure before and after infusion of lifileucel. Withhold or discontinue lifileucel infusion if severe acute respiratory failure is evidenced.

References

  1. (2024) "Product Information. Amtagvi (lifileucel)." Iovance Biotherapeutics Manufacturing LLC

Amtagvi drug interactions

There are 256 drug interactions with Amtagvi (lifileucel).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer